{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:16:51Z","timestamp":1754162211804,"version":"3.41.2"},"reference-count":53,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71673004 and 71911530221"],"award-info":[{"award-number":["71673004 and 71911530221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020371","name":"Beijing New Sunshine Charity Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020371","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to estimate the cost-effectiveness of direct-acting antivirals (DAAs) among patients with non-genotype 1 for the eradication of hepatitis C virus (HCV) infection in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A decision-analytic Markov model was developed to estimate the lifetime costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) for DAAs and pegylated interferon plus ribavirin (PEG-RBV) from a societal perspective. The model inputs were derived from the literature, a patient survey, HCV expert opinions and a specialised drug price database available in China. Sensitivity analysis was conducted to evaluate the model robustness and calculate reasonable prices of DAAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For patients infected with HCV genotype 2, the pan-genotypic regimen sofosbuvir\/velpatasvir (SOF\/VEL) was the most cost-effective strategy compared with PEG-RBV, with an ICER of US$5653\/QALY. For genotype 3, the combination of sofosbuvir plus daclatasvir (SOF-DCV) was the most cost-effective approach, with an ICER of US$3314\/QALY. All DAA regimens for genotype 6 were cost-saving, and sofosbuvir plus ribavirin (SOF-RBV) was the optimal regimen. One-way sensitivity analysis demonstrated that the ICERs were most sensitive to the utility values, discount rate and drug costs. Probabilistic sensitivity analysis indicated that using a threshold equal to one time the gross domestic product (GDP) per capita in China (US$9769\/QALY, 2018), the probability of SOF\/VEL, SOF-DCV and SOF-RBV being cost-effective was 58%, 83% and 71% for genotype 2, 3 and 6, respectively. Threshold analysis showed that the price of DAAs should be reduced by some degree to achieve better affordability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DAAs were cost-effective compared with traditional treatments. A reasonable reduction in the price of DAAs will increase drug affordability and is of great significance as a global strategy to eradicate viral hepatitis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2020-003194","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T15:35:10Z","timestamp":1606491310000},"page":"e003194","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective"],"prefix":"10.1136","volume":"5","author":[{"given":"Xia","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Health policy and management, School of Public Health, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Health policy and management, School of Public Health, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0640-2003","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Health policy and management, School of Public Health, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"2025072915190648000_5.11.e003194.1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025072915190648000_5.11.e003194.2","unstructured":"World Health Organization . Global hepatitis report, 2017. Available: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ [Accessed 10 Nov 2019]."},{"key":"2025072915190648000_5.11.e003194.3","unstructured":"World Hepatitis Alliance . HCVQUEST, global patient survey, Country-Specific report, China. Available: http:\/\/www.worldhepatitisalliance.org\/sites\/default\/files\/resources\/documents\/HCV%20Quest%20China%20%28EN%29.pdf [Accessed 10 Nov 2019]."},{"key":"2025072915190648000_5.11.e003194.4","unstructured":"World Health Organization . Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000-2016. Available: https:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates\/en\/ [Accessed 10 Nov 2019]."},{"key":"2025072915190648000_5.11.e003194.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ396"},{"key":"2025072915190648000_5.11.e003194.6","first-page":"962","article-title":"[Guidelines for the prevention and treatment of hepatitis C (2019 version)]","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"2025072915190648000_5.11.e003194.7","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12398"},{"key":"2025072915190648000_5.11.e003194.8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40258-012-0002-0","article-title":"Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model","volume":"11","author":"McEwan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"2025072915190648000_5.11.e003194.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26304"},{"key":"2025072915190648000_5.11.e003194.10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3111\/13696998.2015.1106546","article-title":"Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada","volume":"19","author":"Moshyk","year":"2016","journal-title":"J Med Econ"},{"key":"2025072915190648000_5.11.e003194.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175189","article-title":"Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"2025072915190648000_5.11.e003194.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2017.03.012"},{"key":"2025072915190648000_5.11.e003194.13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/jgh.14301","article-title":"Cost-effectiveness of generic pan-genotypic sofosbuvir\/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment","volume":"33","author":"Goel","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025072915190648000_5.11.e003194.14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/03007995.2018.1546678","article-title":"Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C","volume":"35","author":"Wu","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025072915190648000_5.11.e003194.15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2014.07.003","article-title":"Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study","volume":"27","author":"Li","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2025072915190648000_5.11.e003194.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2820-z"},{"key":"2025072915190648000_5.11.e003194.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100128","article-title":"Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2025072915190648000_5.11.e003194.18","unstructured":"Wells G , Kelly S , Farah B , et al . CADTH therapeutic reviews. drugs for chronic hepatitis C infection: clinical review. Ottawa (on): Canadian agency for drugs and technologies in health, 2016."},{"key":"2025072915190648000_5.11.e003194.19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jvh.13033","article-title":"Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: real-world experience of a retrospective study","volume":"26","author":"Wu","year":"2019","journal-title":"J Viral Hepat"},{"key":"2025072915190648000_5.11.e003194.20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003004","article-title":"Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"key":"2025072915190648000_5.11.e003194.21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/apt.13429","article-title":"Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong","volume":"43","author":"Lai","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025072915190648000_5.11.e003194.22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jgh.14102","article-title":"Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: results from a phase 3B study in China","volume":"33","author":"Wei","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025072915190648000_5.11.e003194.23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025072915190648000_5.11.e003194.24","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2025072915190648000_5.11.e003194.25","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"2025072915190648000_5.11.e003194.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ220"},{"key":"2025072915190648000_5.11.e003194.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"2025072915190648000_5.11.e003194.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"2025072915190648000_5.11.e003194.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.006"},{"key":"2025072915190648000_5.11.e003194.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.005"},{"key":"2025072915190648000_5.11.e003194.31","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200205000-00018"},{"key":"2025072915190648000_5.11.e003194.32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MEG.0b013e32834dda64","article-title":"Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein","volume":"24","author":"Liu","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025072915190648000_5.11.e003194.33","first-page":"2157","article-title":"Natural history of liver cirrhosis in South China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J"},{"key":"2025072915190648000_5.11.e003194.34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/hepr.13364","article-title":"Liver transplantation in Japan: registry by the Japanese liver transplantation Society","volume":"49","author":"Umeshita","year":"2019","journal-title":"Hepatol Res"},{"key":"2025072915190648000_5.11.e003194.35","unstructured":"World Health Organization . Life tables of the world Health organization member states, 2016. Available: http:\/\/apps.who.int\/gho\/data\/view.main.60340?lang=en [Accessed 10 Nov 2019]."},{"key":"2025072915190648000_5.11.e003194.36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.038257"},{"key":"2025072915190648000_5.11.e003194.37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir306"},{"key":"2025072915190648000_5.11.e003194.38","unstructured":"Yaozhi. Available: https:\/\/db.yaozh.com\/ [Accessed 10 Nov 2019]."},{"key":"2025072915190648000_5.11.e003194.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155934","article-title":"Will sofosbuvir\/ledipasvir (Harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? an economic analysis using real-world data","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"2025072915190648000_5.11.e003194.40","unstructured":"Gao Q . Economic analysis for liver and renal transplant in a transplant center [A master\u2019s degree] [in Chinese]. Central south university, 2007."},{"key":"2025072915190648000_5.11.e003194.41","first-page":"438","article-title":"The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting","volume":"19","author":"Manos","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2025072915190648000_5.11.e003194.42","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315240"},{"key":"2025072915190648000_5.11.e003194.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40976.x"},{"key":"2025072915190648000_5.11.e003194.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.009"},{"key":"2025072915190648000_5.11.e003194.45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"2025072915190648000_5.11.e003194.46","first-page":"21","article-title":"Task group of the Chinese guidelines for pharmacoeconomic evaluations. China guidelines for pharmacoeconomic evaluations","volume":"03","year":"2011","journal-title":"China Journal of Pharmaceutical Economics"},{"key":"2025072915190648000_5.11.e003194.47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0373-9","article-title":"Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals","volume":"34","author":"Chhatwal","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2025072915190648000_5.11.e003194.48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/apt.14271","article-title":"Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6","volume":"46","author":"He","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025072915190648000_5.11.e003194.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035224","article-title":"Cost-Utility of sofosbuvir\/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1B infection in China","volume":"10","author":"Yun","year":"2020","journal-title":"BMJ Open"},{"key":"2025072915190648000_5.11.e003194.50","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00005"},{"key":"2025072915190648000_5.11.e003194.51","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0602"},{"key":"2025072915190648000_5.11.e003194.52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40273-019-00864-8","article-title":"Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis","volume":"38","author":"Mattingly","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2025072915190648000_5.11.e003194.53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03007995.2016.1222512","article-title":"Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan","volume":"33","author":"Igarashi","year":"2017","journal-title":"Curr Med Res Opin"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2020-003194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:19:17Z","timestamp":1753827557000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2020-003194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjgh-2020-003194"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2020-003194","relation":{},"ISSN":["2059-7908"],"issn-type":[{"type":"electronic","value":"2059-7908"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}